1. Academic Validation
  2. Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations

Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations

  • J Pharm Sci. 2008 Feb;97(2):883-92. doi: 10.1002/jps.21146.
Steven W Baertschi 1 Heiko Brunner Charles A Bunnell Gary G Cooke Benjamin Diseroad Douglas E Dorman Patrick J Jansen Craig A J Kemp Steven R Maple Karen A McCune Jeffrey L Speakman
Affiliations

Affiliation

  • 1 Eli Lilly and Company, Analytical Sciences Research and Development, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.
Abstract

Two impurities found in both stressed and aged solid-state formulations of olanzapine have been identified as (Z)-1,3-dihydro-4-(4-methyl-1-piperazinyl)-2-(2-oxopropylidene)-2H-1,5-benzodiazepin-2-one (1) and (Z)-1-[1,2-dihydro-4-(4-methyl-1-piperazinyl)-2-thioxo-3H-1,5-benzodiazepin-3-ylidene]propan-2-one (2). The structures indicate that the two impurities are degradation products resulting from oxidation of the thiophene ring of olanzapine. The impurities were isolated by preparative HPLC from a thermally stressed formulation, and characterized by UV, IR, MS, and NMR. A synthetic preparation of compounds 1 and 2 by reaction of olanzapine with the singlet oxygen mimic 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) is presented. The structure of 2 was also determined by single-crystal X-ray diffraction analysis. A degradation pathway for the formation of 1 and 2 is proposed.

Figures
Products